A Phase 2 interventional study of Radiotherapy, Temozolomide, Doxorubicin in Glioblastoma, sponsored by Iacopo Sardi. Recruiting at 1 site in Italy. Open to participants aged 3 Years to 30 Years. Per ClinicalTrials.gov, last updated 2024-03-07.
Sponsored by Iacopo Sardi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.
Among the 232 studies testing temozolomide in Glioblastoma, this one is the 167th largest by planned enrollment of the 221 interventional ones that give a count, is one of 9 that started in 2022, is one of 99 in phase 2, reaches primary completion later than 18 of the 34 other live ones, and was the 220th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 16+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
Rigel Pharmaceuticals · Sites in United States, Australia, Canada and 4 more countries
Ages 12–39
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 3 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 110 · Phase 2 140 · Phase 3 16 · Phase 4 2
First in 1997; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 41 across the 221 interventional studies. Of the 168 that completed or were terminated, 69 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 232 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Iacopo Sardi as lead sponsor.
Iacopo Sardi has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
4 of the studies testing temozolomide in Glioblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04019262John FlickingerShort Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | 2026-12 |
| NCT04623931M.D. Anderson Cancer CenterChemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | 2026-12-31 |
| NCT07193654Second Affiliated Hospital, School of Medicine, Zhejiang UniversityStupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | 2027-04-01 |
| NCT06297512Iacopo SardiEvaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | 2027-11-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 232 studies testing temozolomide in Glioblastoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Glioblastoma (GBM) and diffuse intrinsic bridge gliomas (DIPG) only the most aggressive forms of cancer, and their prognosis remains bleak. Currently, the standard of treatment is TMZ concomitant with radiotherapy, and, at the end of combined treatment, as adjuvant therapy. In vitro and in vivo experimental studies have suggested that anthracyclines are effective antineoplastics for the treatment of gliomas. In patients with solid tumors treated with anthracyclines, continuous infusion administration compared with bolus administration has been shown to provide a better safety profile especially with regard to cardiotoxicity. Based on this evidence, this study aims to evaluate the safety and antitumor activity of combined treatment with Dox, WBRT (whole body radiotherapy), and TMZ in pediatric and young adult patients affected by GMB
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Whole therapy radiation therapy * Temozolomide concomitant * After 1 month adjuvant Temozolomide, * After 3 months Doxorubicine * adjuvant Temozolomide
Drug: Radiotherapy, Temozolomide, Doxorubicin
Drug pages: TemozolomideStudies of TemozolomideTemozolomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DoxorubicinStudies of DoxorubicinDoxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Radiation treatment Concomitant TMZ: 75mg/m2/day per OS for 7 days per week, from the first day of radiotherapy to the last (maximum cumulative dose 3150mg/m2), with possibility of earlier initiation on clinician's judgment. After 1 month (4-5 weeks ± 7 days) from the end of RT/TMZ treatment they will receive: Adjuvant TMZ: 2 cycles at increasing doses (150-180 mg/m2) per OS for 5 consecutive days 28 days apart After 3 months (12 weeks ± 7 days) from the end of RT/TMZ treatment they will receive: Dox 4 cycles with 37.5mg/m2/day by continuous infusion over 48 hours (2 days) every 28 days (maximum cumulative dose 300mg/m2) And after 4 weeks ± 7 days from the end of Dox treatment they will receive: TMZ adjuvant 12 cycles at increasing doses (150-180 mg/m2) by OS for 5 consecutive days 28 days apart (maximum cumulative dose 16200 mg/m2);
Evaluation prolonged Dox
Time to early withdrawal from experimental treatment with Dox
Time frame: through study completion, an average of 1 year
Percentage of Withdrawal from the study rate
Percentage of subjects with SAE leading to withdrawal from the study
Time frame: through study completion, an average of 1 year
Percentage of SAEs
Percentage of SAEs
Time frame: through study completion, an average of 1 year
Mortality rate
Mortality from adverse events
Time frame: through study completion, an average of 1 year
Early discontinuation of dox treatment rate
Proportion of early discontinuation of experimental treatment with Dox
Time frame: through study completion, an average of 1 year
Event-free survival (EFS), disease progression (PFS), and overall survival (OS)
Event-free survival (EFS) calculated as the time between the date of enrolment and the date of occurrence of one of the events: * disease progression established according to the modified RANO criteria for paediatric age * clear progression of non-measurable lesions (T1); * - any new lesion; * clinical deterioration due to the tumour and not attributable to other causes (e.g, seizures, adverse drug effects, complications of therapy, cerebrovascular events infections and so on); * failure to return for evaluation following death (from any cause) or deterioration of condition; * and other described in the protocol
Time frame: through study completion, an average of 1 year
Started Dec 2022 (actual). Primary completion is estimated for Nov 2027, 59 months after the start.
Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 59 months is close to that.
Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Temozolomide · Doxorubicin